A Phase 3 interventional study of Oral iron tablets and VIT-45 in Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2018-02-05.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.
Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 15th largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 4th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:
Biocruces Bizkaia Health Research Institute · Sites in Spain
Ages 18+
Children's Hospital of Orange County
Ages 1–18
Helsinki University Central Hospital
Ages 18+
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 24 · Phase 4 23
First in 2005; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 361 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 156 across the 54 interventional studies. Of the 45 that completed or were terminated, 13 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
19 studies in Anemia by Daiichi Sankyo: none open now, none under way, none of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 19 studies in Anemia by Daiichi Sankyo, this one is the 7th largest by enrollment, is one of 6 that started in 2005, is one of 15 in phase 3, and was the 10th registered.
Daiichi Sankyo’s Anemia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing ferric carboxymaltose in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 19 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compares the safety and efficacy of intravenous iron vs oral iron in subjects who display postpartum anemia.
This is an open label, Phase III, randomized, active controlled study of intravenous iron vs oral iron in anemic post partum patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
Drug: VIT-45
325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
Drug: Oral iron tablets
325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
Also known as: Ferrous Sulfate
A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
Number of Subjects Who Achieved 'Success' Meaning a ≥ 2.0 Increase in Hemoglobin
Time frame: anytime between baseline and the end of study or time to intervention
Hospitals and medical clinics
| Milestone | VIT-45 | Oral Iron Tablets |
|---|---|---|
| Started | 174 | 178 |
| Completed | 165 | 162 |
| Not completed | 9 | 16 |
| participants | VIT-45 | Oral Iron Tablets |
|---|---|---|
| Number of Subjects Who Achieved 'Success' Meaning a ≥ 2.0 Increase in Hemoglobin | 162 | 159 |
Collected over 9 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VIT-45 | — | 4/174 (2.3%) | 40/174 (23%) |
| Oral Iron Tablets | — | 4/178 (2.2%) | 61/178 (34.3%) |
| Event | VIT-45 | Oral Iron Tablets |
|---|---|---|
| Peripartum cardiomyopathyPregnancy, puerperium and perinatal conditions | 1/174 | 0/178 |
| Cardiac failureCardiac disorders | 1/174 | 0/178 |
| Postoperative infectionInfections and infestations | 1/174 | 0/178 |
| AppendicitisInfections and infestations | 1/174 | 0/178 |
| CholecystitisHepatobiliary disorders | 1/174 | 0/178 |
| Cardiac failure congestiveCardiac disorders | 0/174 | 1/178 |
| ThrombophlebitisVascular disorders | 0/174 | 1/178 |
| Major depressionPsychiatric disorders | 0/174 | 1/178 |
| CholelithiasisHepatobiliary disorders | 0/174 | 1/178 |
| Event | VIT-45 | Oral Iron Tablets |
|---|---|---|
| HeadacheNervous system disorders | 30/174 | 21/178 |
| ConstipationGastrointestinal disorders | 7/174 | 25/178 |
| NauseaGastrointestinal disorders | 3/174 | 15/178 |
| Age, Categorical(Participants) | VIT-45 | Oral Iron Tablets | Total |
|---|---|---|---|
| <=18 years | 15 | 16 | 31 |
| Between 18 and 65 years | 159 | 162 | 321 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | VIT-45 | Oral Iron Tablets | Total |
|---|---|---|---|
| Mean | 26.93 ± 6.36 | 26.03 ± 5.95 | 26.41 ± 6.17 |
| Sex: Female, Male(Participants) | VIT-45 | Oral Iron Tablets | Total |
|---|---|---|---|
| Female | 174 | 178 | 352 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | VIT-45 | Oral Iron Tablets | Total |
|---|---|---|---|
| United States | 174 | 178 | 352 |
The record gives a start of Feb 2005, a primary completion of Nov 2005 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 8 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose